Stockreport

ARS Pharmaceuticals GAAP EPS of -$1.74 beats by $0.02, revenue of $84.28M beats by $2.6M [Seeking Alpha]

ARS Pharmaceuticals, Inc.  (SPRY) 
PDF As of December 31, 2025, ARS Pharma had cash, cash equivalents, and short-term investments of $245.0 million, with 99,290,926 shares of common stock outstanding. The co [Read more]